Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that their new drug application for trastuzumab botidotin, a HER2-directed antibody-drug conjugate for treating HER2-positive breast cancer, has been accepted by China’s National Medical Products Administration. This drug, which showed significant improvement in progression-free survival in a phase III study compared to T-DM1, represents a potential advancement in cancer treatment, although the company cautions that successful development and commercialization are not guaranteed.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a company incorporated in the People’s Republic of China that operates in the biopharmaceutical industry. It focuses on developing antibody-drug conjugates (ADCs) for cancer treatment, with a market emphasis on innovative therapies for conditions such as HER2-positive breast cancer.
YTD Price Performance: -0.18%
Average Trading Volume: 353,420
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$29.77B
See more data about 6990 stock on TipRanks’ Stock Analysis page.
Trending Articles
- Microsoft Attracts Analysts’ Buy Ratings Despite High AI Capex Plans
- Warner Bros’ Discovery+ Service is Becoming Dearer by $1
- Apple Eyes News App’s Expansion to Earn More Revenues
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
